Translation Sessions, Wednesday August 15, 2018, 1-Day parallel sessions

The clinical application of new research findings & technologies raises a wide range of complex issues. Regulatory aspects, GMP manufacturing, standardization etc. are amongst others key issues. The translation sessions will bring together experts and researcher aiming to debate about these challanges.

Discuss strategies to master the steps and processes involved in translating advances in basic science from bench to bedside:

  • How can Researchers & startup executives in the translation process benefit from institutions which facilitate access to critical ressources and alliance programs?
  • What funding offers are there for this purpose?

The morning session provides a cross-section of important institutions that provide targeted support for translational projects from research to clinics and/or to market. The USPs of the individual institutions and the conditions of access will be presented. Success stories from research projects and start-ups will illustrate the benefits of the individual offers.

The first afternoon session will then deal with success factors of cooperation between actors in the translation process. The three perspectives of researchers, clinicians and industry and effective cooperation patterns will also be the subject of a concluding panel discussion.

The second afternoon session will set the focus on regulatory barriers and the professional handling of them. Experts will show how to prepare for issues concerning the commercialization of new technologies during the translation phase.

  Download the preliminary Program with the Translational Sessions


Wednesday, August 15 (Session 15B)


08:00 – 08:30

Registration (University of Zurich, Entrance Hall)


Conference Day 2 Plenary Talk KOH-B-10, floor B, video transmission to KOL-G-201 (Aula), floor G


08:30 – 09:10

Keynote 5

Matthias Lutolf, EPFL, Lausanne, CH Engineering the microenvironment with biomaterials

Intro: Georg Duda, Charité, Berlin, DE


Session 5B: Translational Session 1: Interfaces in the education and translation from science & technology to clinics & market:   KOL-G-201 (Aula), floor G

Chair: Alex Dommann, Empa, CH


09:10 – 09:30

Invited Translation- Contribution 1

Corina Schütt, Hochschulmedizin Zurich, CH

Zurich Heart

09:30 – 09:50

Invited Translation- Contribution 2

Uwe Freudenberg, Max Bergmann Center of Biomaterials, Dresden, D


09:50 – 10:10

Invited Translation- Contribution 3

Stefan Fischer, Euresearch


10:10 – 10:40

Coffee/Tea Break / Lichthof, floor D


Session 5B (continued): Translational Session 1: Interfaces in the education and translation from science & technology to clinics & market: KOL-G-201 (Aula), floor G

Chairs: Daniel Ricklin, University Basel, CH / Aylvin Dias, DSM Materials Science Center BV, NL


10:40 – 11:20

Invited Translation-Contribution 4

Martin Kayser, Wyss Zurich, CH

The Wyss Zurich model and challenges for translational medicine

Maximilian Emmert, Wyss Zurich Project «LifeMatrix»

Showcase project «LifeMatrix»

11:20 – 11:35

Invited Translation-Contribution 5

Christian C. Mathis, SuSoS AG

Molecular pocket-knife for next-generation diagnostics

11:35 – 12:10

Invited Translation-Contribution 6

Stephan Emmerth, Baselaunch, Jakob Busch-Petersen, F. Hofmann-La Roche AG

BaseLaunch and the role of incubators

Simon Ittig, T3 Pharmaceutical AG

A versatile bacterial cancer therapy: from idea to company


12:10 – 13:30

Lunch & Poster Session &   Exhibition / Lichthof, floor D, Foyer West, floor D


Session 6B: Translational Session 2: Sources of Innovation   KOL-G-201 (Aula), floor G

Chairs: David W. Grainger, University of Utah, USA, Michelle Grandin, representing AMI-USC, LA, USA


13:30 – 13:45

Invited Translation-Contribution 7

Daniela Marino, Wyss Zurich Project «denovoSkin»

Personalized tissue therapy: challenges and opportunities

13:45 – 14:00

Invited Translation-Contribution 8

Daniel Delfosse, Mathys AG Bettlach, CH

Cooperation is the key for successful innovation

14:00 – 14:15

Invited Translation-Contribution 9

Curzio Rüegg, Novigenix AG, University of Fribourg CH

Cancer diagnostics: translating an idea into a product

14:15 – 14:30

Invited Translation-Contribution 10

Patrick Kugelmeier, Kugelmeiers AG, Zollikerberg, CH

How laws of nature should guide the development of 3D cell culture for regenerative medicine

14:30 - 15:10

Panel Discussion

Discussion Leader: David W. Grainger, University of Utah, USA Panelists: Speakers of above

15:20 – 15:50

Coffee/TeaBreak / Lichthof, floor D


Session 7B: Translational Session 3: Crossing regulatory and institutional barriers KOL-G-201 (Aula), floor G

Chairs: Samuele Tosatti, SuSoS AG, CH, Martin Schuler, AO Foundation, CH


15:50 – 16:05

Invited Translation-Contribution 11

Peter Studer, SwissMedtech, CH

The new EU-regulations and their impact on startup companies

16:05 – 16:20

Invited Translation-Contribution 12

Martin Schuler, AO Foundation CH

Surviving the new MDR

16:20 – 16:25

Invited Translation-Contribution 13

Beat Lechmann, Johnson & Johnson Medical Devices

MDR/IVDR implementation: what does it mean for my company?

16:25 – 16:40

Invited Translation-Contribution 14

Wendelin Stark, Hemotune AG

MDR what does this mean for a startup company

16:40 – 16:50



16:50 – 17:00


Short break (no servings)



Conference Day 2 Plenary Talk KOH-B-10, floor B, video transmission to KOL-G-201 (Aula), floor G

17:00 – 17:40

Keynote 7

David J. Mooney, Harvard University, Cambridge, MA, USA Viscoelasticity and stem cells

Intro: Michaela Kneissel, Novartis, Basel, CH

18:30 –  23:00

Conference Dinner (Restaurant “Die Waid”, Zurich)